INVOKANA ® (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease
Late-breaking renal data from the integrated CANVAS Program presented at the American Society of Nephrology Kidney Week 2017 Annual Meeting
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Canagliflozin | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Invokana | Pharmaceuticals | Urology & Nephrology